Clinical Trial Detail

NCT ID NCT02900664
Title A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

colorectal cancer

lung non-small cell carcinoma

triple-receptor negative breast cancer

Therapies

Nazartinib + Spartalizumab

CJM112 + Spartalizumab

Spartalizumab + Trametinib

Canakinumab + Spartalizumab

Canakinumab

Age Groups: adult senior

No variant requirements are available.